Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases. Launched in 2024, Mirador has raised over $400 million from leading life sciences investors and is based in San Diego, CA. 

Life Sciences

Mirador Therapeutics

Mark McKenna

Tim Andrews

Olivier Laurent

Maulik S.

Vika Brough

Nori Ebersole

Jordan Zwick

Allison Luo

The Research and Development team at Mirador Therapeutics focuses on discovering and advancing new precision medicines for chronic immune-mediated inflammatory and fibrotic diseases. Leveraging Mirador360™ and the latest in human genetics and data science, the team, led by prominent experts such as the Chief Scientific Officer, Richard Graham, Ph.D., and William Sandborn, M.D., drives innovation from early-stage research through clinical development.

Research and Development

Leadership Team

Research and Development

About

Team members

Other teams at Mirador Therapeutics

Leadership Team